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Abstract 
To better understand urinary inhibitors of calcium 
oxalate crystallization, both z.eta potential measurement 
and particle siz.e analysis were chosen to illustrate: (1) 
the potential therapeutic efficacy of G872, a semi-syn-
thetic sulfated polysaccharide, in stone prevention; and 
(2) the relative contribution of various urinary fractions 
{e.g., ultrafiltered urine (UFU), Tamm-Horsfall protein 
(THP), urinary polyanionsprecipitated with cetylpyridin-
ium chloride (CPC), urinary macromolecular substances 
with different concentration ratios (UMSl0,50,90 and 
UMS'l0,50,90) and THP-free urine (THPFU)} to total 
urinary inhibitory activity. The results showed: (1) ad-
dition of G872 significantly enhances urinary inhibitory 
activity and negative z.eta potential values; (2) re-addi-
tion of the CPC to UFU completely restores urinary in-
hibitory activity; and (3) artificial urines prepared by 
mixing UMS' 10,50,90 from THPFU with UFU differed 
in inhibitory activity from that prepared by mixing 
UMSl0,50,90 from a pooled normal urine with UFU. 
Based on these experimental results, the following spec-
ulations can be made: (1) normal human urines are con-
sidered to be a protective colloidal system; (2) urinary 
inhibitory activity originates mainly from CPC and/or 
UMS; (3) normal THP is a protective material to main-
tain urinary inhibitory activity; and (4) mutual interac-
tion between urinary inhibitors may change the total uri-
nary inhibitory activity. 
Key Words: Zeta potential, calcium oxalate, crystalli-
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Introduction 
From a physico-chemical viewpoint the main factors 
dealing with renal stone formation in the overall urinary 
tract can be summariz.ed in eq. (1) [11], 
4> = 4> (X, Y, Z) (1) 
where 4> is the function describing a risk tendency for 
suffering from stone disease. Three variables are in-
volved in this function which may determine the stone 
formation risk of an individual: X, the supersaturation of 
stone salts in urine (a thermodynamic parameter); Y, the 
urinary inhibitory activity against stone salts crystalliza-
tion (a kinetic parameter); and Z, the crystal retention to 
urinary-tract epithelium cells (a colloid and interfacial 
chemical parameter) . 
In the past decade, the early events of stone forma-
tion as well as the roles of renal tubule cells in nephroli-
thiasis have been emphasiz.ed [24]. For the situation in-
side a nephron, a equation, similar to eq. (1), can be 
formulated {eq. (2)}, 
4> = 4> (x, y, z) (2) 
where 4> has the same meaning as in eq. (1). Three var-
iables (x, y, z) associate to early events of stone forma-
tion occurring within the kidney. They are the renal 
handling of stone salt ions (x), synthesis/secretion of 
modifiers of stone salts crystallization (y) and cell-crystal 
interaction (z). Comparing eq. (2) to eq. (1), one may 
find the corresponding relationship between the two the-
ories of stone formation (X, Y, Z versus x, y, z). 
Current opinion seems more and more to emphasiz.e the 
importance of cellular and molecular levels [6]. 
It has been known that different behaviors of stone 
salt crystallization inside a nephron are associated with 
the properties of the interfaces between crystals and their 
surrounding liquids and between renal epithelial cells 
and their surroundings. Since the additivity of urinary 
inhibitors exists only in the mass, but not in their func-
tions { eqs. (3) and ( 4)}, the following two factors should 
be considered: (1) the urinary environment such as uri-
nary components, pH, ionic strength and supersaturation 
L.C. Cao et al. 
Table 1. Artificial urine composition (A:B = 1: 1). 
A: solution 
Salt 
CaCl2·2H2O 
NaiSO4 
MgSO4-7H2O 
NH4CL 
KCl 
B: solution 
Salt 
NaH2PO4 ·2H2O 
NaiHPO4 
Na3Citrate·2H2O 
NaCl 
NaiC2o/ 
g/1 
1.765 
4.862 
1.460 
4.643 
12.133 
g/1 
6.800 
0.869 
1.168 
13.51 
0.166 
pH= 6.10; ionic strength = 0.33; 
relative supersaturation of calcium oxalate = 1.29; 
•sodium oxalate was excluded from actual applied 
solution in this study. 
may have an influence on the inhibitory activity of a 
given urinary inhibitor; and (2) the interaction between 
two given inhibitors may have an influence on the total 
urinary inhibitory activity. 
le m 
MTotal = ~ M(LM)i + ~ M(SM\ (3) 
I I 
le m 
!Total -;rt. ~ I(LM)i + ~ I(SM)j (4) 
I I 
in which MTotal is the total mass of inhibitors in a given 
urine; E M(LM)i is the total mass of various macro-
molecular inhibitors in the urine (i = 1.. .k); E M(SM)j 
is the total mass of various small molecular inhibitors in 
the urine (j = 1...m). Whereas !Total is the total urinary 
inhibitory activity, E I(LM)i is the total contribution of 
i kind of macromolecular substances (LM) to the inhibi-
tory activity (i = 1.. .k), and E I(SM)j is the total con-
tribution of j kind of small molecular substances (SM) to 
the inhibitory activity (j = 1.. .m). 
Supportive findings have been reported: (1) A given 
macromolecular substance such as Tamm-Horsfall pro-
tein (THP) shows a dual effect (inhibition and promo-
tion) on stone salt crystallization under different experi-
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mental conditions depending on pH, ionic strength, cal-
cium and citrate [17, 18, 20, 25]; (2) the same kind of 
material, but with a different molecular weight or exist-
ing state in solution, shows a different behavior to inhi-
bition or promotion in calcium phosphate crystallization 
under identical experimental conditions [23]; and (3) a 
mixture of two different kinds of macromolecular inhibi-
tor does not demonstrate a total inhibitory activity equal 
to the sum of their individual capacities ( our unpublished 
data). These phenomena suggest that binding of urinary 
small or macromolecular inhibitors on stone salts crys-
tals could determine their functions in stone salts crystal-
lization. 
In the present study, a modification of the zeta po-
tential measurement is introduced. Three urinary pa-
rameters: inhibitory activity against calcium oxalate 
monohydrate (COM) crystal growth (IG) and agglomera-
tion (IA), and zeta potential (ZP) have been chosen as 
markers to evaluate urinary inhibitor properties. Urine 
samples were collected from 10 stone-formers (SF) and 
10 non-stone-formers (NSF) to define their inhibitory ac-
tivity and ZP values in the presence and absence of 
G872. After the measurements, all NSF urines were 
pooled (pooled normal urine, PNU) for preparation of 
various urinary fractions including ultrafiltered urine 
(UFU), THP, THP-free urine (THPFU), urinary polyan-
ions (CPC), as well as urinary macromolecular substanc-
es obtained form the whole urine (UMS) and from 
THPFU (UMS'). UMS and UMS' were tested at sever-
al concentrations: 10, 50 and 90 % . 
To better understand urinary inhibitors of calcium 
oxalate crystallization, the inhibitory activity of the 
pooled urines as well as their fractions has been studied. 
Special attentions will be paid to answer: (1) whether a 
exogenous semi-synthetic sulphated polysaccharide such 
as G872 may significantly enhance urinary inhibitory ac-
tivity? (2) which urinary components contribute most to 
total urinary inhibitory activity? (3) what are characteris-
tics of urinary inhibitors in human? and ( 4) what are the 
factors that may influence urinary inhibitory activity? 
Materials and Methods 
Zeta potential measurement 
The principle and method of ZP measurement has 
been described elsewhere [2, 5]. In this study, a meth-
odological modification was made. COM crystals were 
first incubated with whole urine, and the crystals coated 
by urinary inhibitors were washed and re-suspended to 
an artificial urine. The procedure can be described as 
follows: 1 ml urine sample was mixed with 50 µl of the 
COM seed crystal suspension (24 mg/ml). After incuba-
tion of the mixtures at 37°C with shaking for 2 hours, 
the crystals were collected by centrifugation and washed 
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Figure 1. A schematic diagram of the preparations of urinary fractions from a pooled normal urine (PNU), the 
meaning of various symbols is: CPC: urinary polyanions precipitated with cetylpyridinium chloride; THP: Tamm-
Horsfall protein isolated by adsorption with diatomaceous earth; THPFU: THP-free urine prepared by using the filter 
procedure with the earth; UMS or UMS': Urinary macromolecular substances prepared from original PNU or THPFU 
by using the ultrafiltration procedure; UFU: ultrafiltered urine; and MU/MU' 10,50,90: mimic urines. These mimic 
urines were prepared by mixing of urinary macromolecular substances (UMS/UMS' 10,50,90) with UFU, according to 
a given UFU to UMS/UMS' ratio's in volume. It should be noted that the composition of all mimic urines should be 
the same as corresponding to their original urines (PNU or THPFU). 
two times with a solution saturated with calcium oxalate. 
The collected and washed COM crystals were re-sus-
pended into 3 ml of 5 times diluted artificial urine (com-
position listed in Table 1). The mean ZP and ZP distri-
bution of the COM crystals coated by urinary inhibitors 
were measured using the Coulter DELSA 440 (Coulter 
Electronics Ltd., Luton, U.K.). 
To illustrate the effect of an addition of G872 to 
urine on the COM zeta potential, the same procedure 
was applied with addition of G872 (5 mg/1) to each urine 
tested. The method was also used in mimic urines pre-
pared by mixing the UFU with urinary fractions such as 
THP, UMS, CPC and G872. 
Inhibitory activity measurement 
A COM seeded crystal growth system based on par-
ticle size determination (Coulter Multisizer II) together 
with a mathematical model as described by Ryall [26, 
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27] was chosen to address the inhibitory activity of 
crystal growth and agglomeration for a given urine and 
urinary fractions as well as other additives. 
Urinary fraction preparation 
The fresh morning urines (8:00-12:00 a.m.) were 
collected without preservative from 10 patients with cal-
cium oxalate nephrolithiasis and 10 normal subjects. 
For determination of urinary inhibitory activity and ZP, 
5 ml urines from each samples were centrifuged at 1500 
g for 10 minutes and stored at -20°C until used. Re-
maining large volume urines of each sample were store 
at 4°C. The individual 10 normal urines were pooled 
and divided into three portions which were subjected to 
several procedures as described in Figure 1. Urinary 
GAGs concentration of the PNU was determined with 
dimethylmethylene blue-based spectrophotometry [10). 
(a) The first portion of the PNU (100 ml) was ultra-
LC. Cao et al. 
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Figure 2. Scatter diagrams of data: (a) inhibitory 
activity of COM crystal agglomeration (IA%) in stone 
formers (SF) and non-stone formers (NSF) as well as 
the alterations of the inhibitory activity after addition of 
G872 (5 mg/I) to corresponding urines (bold line and 
box); (b) inhibitory activity of COM crystal growth 
(JG%); and (c) negative zeta potential values (ZP). The 
central box covers the middle 50 % of the data values, 
between the upper and lower quartiles. The "whiskers" 
extend to the minimum and maximum values, and the 
central line is at the median. Extreme values are plotted 
as separate points useful for detecting outlier and 
asymmetric behaviour. NS: no statistical significance; 
*: statistically significant, p < 0.001). 
filtered through a membrane with a 5 K.Da M.W. cutoff 
(catalogue no. 887856, Spectrum Medical Industries, 
Inc., Los Angeles, CA) to give an UFU and urinary 
macromolecular substance. During the ultrafiltration, 
the PNU was concentrated. Two milliliters of the con-
centrated urines were respectively collected at the fol-
lowing concentration ratio: 10 % , 50 % and 90 % , which 
were respectively named as urinary macromolecular sub-
stances (UMSlO, UMS50 and UMS90). The remaining 
UFU was kept as medium and stored at 4 °C. 
(b) The second portion (500 ml) was used to isolate 
THP and to prepare THPFU according to Serafini-Cessi 
and associates [30] . Briefly, 5 g of diatomaceous earth 
(Sigma, St. Louis, MO) suspended in deionized water 
was poured into Buchner funnels of 70 mm in diameter 
(Sigma-Aldrich Techware, Bornem, Belgium), lined with 
No. 1 Whatman filter paper. The layer of diatomaceous 
earth is washed first with deionized water and then with 
0.025 M PBS (phosphate buffered saline) of pH 7.5, 
containing 0.14 M NaCl. The urine was filtered 
through the prepared diatomaceous earth layer, and 
THPFU as a filtrate was obtained. To obtained the uri-
nary THP, the diatomaceous earth with THP adsorbed 
was washed with 100 ml PBS, scraped off and resus-
pended in water with stirring occasionally for 30 min-
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utes. The earth suspension was centrifuged at 20,000 g 
for 20 minutes and the supernatant containing THP was 
dialyzed against water and lyophilized. It has been 
shown that the majority of THP present in urine can be 
removed following this procedure. 
The same procedure as described in (a) was applied 
to 100 ml of the THPFU to acquire UMS without THP. 
A second (THP-free) series of urinary macromolecular 
substances (UMS' 10, UMS'50 and UMS'90) is obtained 
according to the ultrafiltration procedure. 
(c) The third portion of PNU (50 ml) and 50 ml 
THPFU obtained from (b) were used to prepare urinary 
polyanions (CPC). Briefly, 1 ml 5 % cetylpyridinium 
chloride (Sigma) was mixed with 50 ml urine (PNU or 
THPFU) and incubated overnight at 4 °C. After centri-
fugation at 10,000 g for 10 minutes, the obtained pellet, 
CPC, was washed twice with absolute ethanol, dried and 
dissolved in 2 M LiCI solution. After other centrifuga-
tion, the supernatant was mixed with ethanol to final 
concentration of 90 % . Following storage of the mixture 
at 4 °C for 48 hours, the final CPC was dissolved in 
deionized water. The concentration of the CPC was 
defined according to de Jong et al. [10]. 
Thus, the original PNU and THPFU as well as four 
isolated fractions including UFU, THP, CPC and uri-
nary macromolecular substances (UMSl0,50,90 and 
UMS' 10,50,90) were obtained. From these fractions, a 
series of mimic urines (MU' 10,50,90 and MUl0,50,90) 
were reconstructed by adding UMS to UFU in the men-
tioned ratio in volume. The preparation procedures are 
summarized in Figure 1. 
Preparation of COM seeded crystals 
COM crystals were prepared as described before 
[5]: one liter of calcium chloride solution (0.25 M) was 
added drop-wise to one liter of sodium oxalate solution 
(0.25 M) over a period of 1 hour at room temperature. 
The COM seed crystals produced were washed several 
times with deionized water until no chloride ions were 
detected. The COM seeded crystal suspension (24 mg/I) 
was prepared and aged at 70°C for 2 hours with stir-
ring. The prepared COM seeded crystals were kept at 
room temperature at least for three weeks before use. 
The COM seeded crystal has been characterized by Phil-
ips APD X-ray diffraction (Philips NV, Eindhoven, 
Netherlands), and their spectrum completely agreed with 
the spectra of commercial available COM. 
Statistical methods 
Determinations were performed in duplicate. A 
statistical software package (STATGRAPHICS V6.0, 
STSC, Inc., Rockville, MD) was chosen to perform the 
Wilcoxon matched-pair signed-rank test (a non-parame-
ter statistical test) and one-way analysis of variance to 
compare the median values of each two groups. 
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Figure 3. Changes in crystal number distributions in the presence and absence of an addition of G872 to an given 
normal urine (No. 5): (a) initial distribution, (b) after 4 hours incubation without any additive, (c) with 2 % urine and 
(d) with 2 % urine plus G872 (5 mg/I) . The data for (b), (c) and (d) were collected from Coulter Multisizer II following 
4 hours of COM seeded-crystal growth in a metastable solution. 
Figure 4. Changes in crystal volume distributions in artificial urine: (a) initial distribution, (b) after 4 hours incubation 
without any additive, (c) with 2 % urine and (d) with 2 % urine plus G872 (5 mg/I). 
-----------------------------------------------------------------------------------
Results 
G872 enhances urinary inhibitory activity and nega-
tive zeta potential values 
Figure 2 shows a comparison of inhibitory activity 
of crystal growth (IG) and agglomeration (IA), and zeta 
405 
potential (ZP) in the urines from stone-formers (SF) and 
non-stone formers (NSF). No significant difference of 
urinary inhibitory activity was found between SF and 
NSF. Only the median of ZP value is significantly high-
er in normal urine than in stone-forming urine (NS = 
-21.4 ± 2.31 vs. NSF = -16.6 ± 2.53 mV; p < 0.05). 
LC. Cao et al. 
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Figure 5. The zeta potential distribution of COM 
seeded crystals in an artificial urine medium following 
incubation with normal urine and urine plus G872 (5 
mg/I). The mean zeta potential values are -23.2 and 
-29.6 mV respectively. 
It was found that addition of 5 mg/I G872 to SF and 
NSF urines significantly enhances the urinary inhibitory 
activity against COM crystal growth and agglomeration 
and the negative zeta potential values, suggesting a po-
tential therapeutic efficacy of G872 in stone prevention. 
In other words, exogenous sulphated polysaccharides, 
e.g., G872, could be useful for stone prevention if such 
compounds can appear unchanged in urine with a suffi-
cient concentration following their (oral) administration. 
The same amount of G872 added to the same vol-
ume of UFU (see Fig. 8, shown later) or to artificial 
urine [7] shows a much higher inhibitory activity and 
negative ZP, emphasizing the importance of the concept 
of net-inhibitory activity again [29] . 
As an example, Figures 3, 4 and 5 demonstrate the 
effect of addition of G872 to a normal urine (No. 5) on 
COM particle size distributions in number (Fig. 3) and 
in volume (Fig. 4), and on zeta-potential distribution 
(Fig. 5) of COM seed crystals. As observed in Figure 
3, after 4 hours incubation the total crystal number and 
portion of small crystal moiety are much higher in the 
presence of G872 than in its absence. Moreover, the to-
tal volume and mean diameter of COM seeded crystals 
are much less in the presence of G872 than in its ab-
sence (Fig. 4). The addition of G872 to this urine (No. 
5) shifts the ZP distribution to more negative direction, 
suggesting these COM seeded crystals can get a high 
negative charge due to the adsorption of G872 to the 
crystal surface (Fig. 5). 
Comparison of inhibitory activity and zeta potential 
value of PNU to its derivatives (THPFU and UFU) 
Figure 6 shows the parameters IG, IA and ZP from 
pooled normal urine (PNU), THP-free urine (THPFU) 
and ultrafiltered urine (UFU). It can be seen that the 
inhibitory activity against crystal agglomeration and 
growth and the negative ZP values are reduced in the 
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Figure 6. Comparison of inhibitory activity against 
crystal growth (IG) and agglomeration (IA), and the zeta 
potential values (ZP) of a pooled normal urine (PNU) 
with its derivatives such as THP-free urine (THPFU) 
and ultrafiltered urine (UFU). 
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Figure 7. Comparison of inhibitory activity (IA, IG) of 
THP-free urine (THPFU) with its corresponding mimic 
urines MU' 10, MU'S0 and MU'90. It should be noted 
that THPFU and all mimic urines prepared have a simi-
lar composition (see text for details). 
UFU, suggesting that UMS (MW > 5000 Da) mainly 
account for urinary inhibitory activity. Although no dif-
ferences of these parameters are found between PNU 
and its corresponding THPFU, the role of THP on COM 
crystallization cannot be ignored. 
Different property of urinary macromolecular sub-
stance derived from between PNU and THPFU 
As compared with the original PNU, no significant 
differences of inhibitory activity (IA and IG) were found 
in the first series mimic urines (MUl0,50,90) prepared 
by re-addition of UMSlO, UMS50 or UMS90 to the 
UFU (not shown), whereas a much lower inhibitory 
activity was found in the second series mimic urines 
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Figure 8. Comparison of inhibitory activity (IA, IG) 
and z.eta potential values of the pooled normal urine 
(PNU) with its corresponding mimic urine including 
UFU, UFU plus G872 5 mg/I (UFU + G), UFU plus 
CPC (UFU + CPC) , UFU plus THP (UFU + THP) 
and UFU plus CPC and THP (UFU + CPC + THP). 
(MU' 10,50,90) prepared by addition of the THP-free 
UMS'lO, UMS'50 and UMS'90 fractions to the UFU 
(Fig. 7). 
Interestingly, the inhibitory activity of these mimic 
urines (MU'50 and MU'90) is much lower than those of 
their original one: THPFU (Fig. 7) and PNU (Fig. 6). 
When we assume that fractionation and recombination 
compose a reversible reaction {eq. (5)}, the prepared 
mimic urine obtained by mixing UFU and UMS 's at a 
given UFU and UMS's ratio (1:9 for UMSlO, 5:5 for 
UMS'50 and 9: 1 for UMS'90) should act similar as the 
THPFU tested at the same concentrations. 
THPFU.,. UFU + UMS'10(50,90) (5) 
However, in the present study, the reconstituted urines 
appear to inhibit less than the original urine. This 
suggests that the reaction described in eq. (5) is an irre-
versible process. It is conceivable that the reduction of 
inhibitory activity in the mimic urines (MU'50 and 
MU'90) is due to denaturalization of the urinary macro-
molecular substances (UMS'50 and UMS'90) during 
their preparation. 
407 
UFU+ 
THP 
UFU+ UFU+ 
CPC+THP G872 
30 ~ 
-t 
m z 
20 ~ 
)> 
r--I 
10 ~ -
0 
Relative contributions of various urinary fractions to 
total urinary inhibitory activity and negative zeta 
potential 
Figure 8 shows the inhibitory activities and negative 
ZP values in ultrafiltered urine (UFU) and their recon-
structed mimic urines, e.g., mixtures of UFU with CPC, 
THP, THP + CPC and G872. As compared with PNU, 
it is obvious that: (1) addition of G872 (5 mg/1) to UFU 
showed the highest potency to increase IA, IG and ZP; 
(2) re-addition of CPC is able to restore the parameters 
to normal (PNU); and (3) re-addition of THP alone does 
not restore inhibitory activity. 
Discussion 
In the past two decades, some important urinary 
macromolecular inhibitors {e.g. , nephrocalcin [21], THP 
[17), uropontin [31), GAGs [l], crystal matrix protein 
(prothrombin activation peptide fragment 1) [33) and in-
ter-a-trypsin protein [32]} have been isolated, purified 
and identified. Some functional differences of these in-
hibitors such as THP and GAGs between SF and NSF 
have also been reported [14, 17). In spite of these ad-
vances, however, we still do not completely understand 
the role of these inhibitors in stone formation. For ex-
ample, some urinary components have demonstrated a 
strong inhibitory effect on both calcium oxalate and cal-
cium phosphate crystallization in various model systems 
in vitro [13, 22), to date, however, no systematic and 
randomiz.ed clinical trails are found in literature to show 
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the significant differences of urinary inhibitory activity 
between SF and NSF. In addition, although the dual ef-
fect of urinary inhibitors has been recognized [4, 14, 23, 
29], little is known about the causes leading to low uri-
nary inhibitory activity. The following open questions 
are listed and are waiting to be answered in further 
investigation: 
(1) What is the molecular defect of urinary inhibi-
tors in stone formers? 
(2) How do the urinary inhibitors play a role in 
pathogenesis of urolithiasis? 
(3) Can the advances of inhibitor theory be used in 
clinical practice for stone prevention? 
Of course, these questions are very wide, and at this 
moment we do not have sufficient knowledge to answer 
all of them. An attempt was made in the present study 
to illustrate the properties of urinary inhibitors and their 
relative contributions to total urinary inhibitory activity . 
The concept that human urine can be a protective 
colloidal system was first put forward by Butt in 1952 
[3]. For many reasons, considering the human urine as 
a colloid system would be better than considering it a 
simple solution. Maintaining the stability of urinary col-
loidal system could be an efficient approach to stone 
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prevention. Zeta potential , as a very sensitive marker, 
has been chosen to study the stability of the urinary col-
loidal system and the mechanisms of crystal agglomera-
tion [2, 5, 8, 16, 17, 28]. In the present study, the 
method of ZP measurement has been modified and used 
successfully. As compared with previous ZP measure-
ment [28], the new method described in this paper en-
ables us to eliminate the interference of urinary pH and 
ionic strength with ZP measurement. Moreover, the 
new ZP measurement could be further used to study the 
interactions between two crystals coated by the same 
and/or different macromolecules in a given medium 
which could be useful for a better understanding of the 
mechanisms of inhibition by urinary macromolecules in-
hibitors in COM crystallization, especially concerning 
COM crystal agglomeration. 
In this study, a significant difference of negative ZP 
values was found between stone-formers and non-stone-
formers (Fig. 2). Moreover, it was observed that addi-
tion of G872 to SF and NSF urines significantly in-
creases in the negative ZP values (Figs. 2 and 5). Re-
addition of CPC to UFU completely restored the urinary 
inhibitory activity (Fig. 8). These findings indicate that 
there is a highly negative charge density on the COM 
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crystals following the adsorption of CPC. The same 
could be observed after G872 addition to UFU. The 
more negative the mean ZP value at the interface be-
tween COM crystals and surrounding solution, the high-
er the dispersion of the COM crystals, which was indeed 
shown by the particle si:ze analysis (Figs. 3 and 4). 
However, we did not find any significant difference 
in the ZP values between PNU and THPFU and its 
mimic urines such as MU' 10,50,90 (not shown), irre-
spective of the big differences in inhibitory activity be-
tween them (Fig. 7). This finding suggested that there 
could be a different binding property between the uri-
nary macromolecular substances in the THPFU and in 
its mimic urines. It also shows that inhibitory potential 
and ZP are two different entities which act and are influ-
enced independently of each other. 
To explain the phenomena, it is necessary to men-
tion the interaction between two separated particles 
which has been described by Finlayson [11] and Robert-
son [29] {see eq. (6)}: 
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(6) 
where VT: the total interaction potential between two 
particles; VA: van der Waals attraction; VR: electrostatic 
repulsion; and Vy: viscous binding. In general, both 
DLVO (Derjaguin, Landau, Verwey and Overbeek) in-
teraction (Fig. 9) [19] and steric interaction (Fig. 10) 
[12] can be taken to understand the stability of urinary 
colloidal system as well as the mechanism of crystal ag-
glomeration. From Figure 9, it can be imagined that in-
crease of ionic strength or reduction of surface charge 
compress the double layer resulting in decreasing of the 
energy barrier which may benefit for crystal agglomera-
tion. In our case, G872 and CPC with high negative 
charge bound to COM crystal surfaces may enhance 
electrostatic repulsion leading to crystal agglomeration 
prevention. Moreover, it is also necessary to emphasi:ze 
that the viscous binding may contribute to the total 
interaction potential by the steric effect, resulting in 
promotion of either crystal dispersion by steric hindrance 
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L.C. Cao et al. 
Disc~ion with Reviewers 
R.L. Ryall: The methodology used to assess inhibitory 
activity is of great concern. This technique was pub-
lished about 14 years ago, and we have since published 
work demonstrating its inability to quantify inhibitory 
activity accurately. One concern is that crystal growth 
and aggregation are not fully independent processes; 
because the amount of CaOx deposited during the reac-
tion is dependent upon the available surface area, crystal 
growth expressed as increasing volume will depend upon 
the degree of aggregation of the crystals. A second 
worry is that the lower limit of detection of the Coulter 
Counter excludes many crystals from being recorded by 
the instrument and this can introduce large errors in the 
calculation of inhibitory activity. These problems can 
only be addressed by use of a computer model to obtain 
accurate estimates of inhibitory activity [39]. Our work 
has been extended by Dr. Michael Hounslow of the De-
partment of Chemical Engineering, University of Cam-
bridge. A non-iterative computer model has been avail-
able for analyzing Coulter Counter data obtained from 
reaction involving simultaneous Ca Ox crystal growth and 
aggregation [38]. For this reason, the data related to in-
hibitory activity measurements are invalid and therefore, 
should not be used. 
G.H. Nancollas: The finding that the addition of G872 
produces more small crystallites (lower crystal volume 
and diameter) with greater zeta potential, may suggest 
secondary nucleation processes at surfaces on which the 
additive molecules have been immobilized. 
H.G. Tiselius: The effects on the inhibition of crystal 
growth and crystal aggregation was measured by its re-
flection in the zeta potential as well as by data derived 
from size distribution in a Coulter Counter. Of these 
two methods, the zeta potential is probably most signifi-
cant because the accuracy of this technique is probably 
greater than that of crystal size analysis. 
Authors: Although the weakness or limitation existing 
in the Coulter Counter model has long been recognized 
by many investigators including ourselves, the model as 
a tool in stone research is still used in many laborato-
ries. We are impressed by Dr. Ryall's special contribu-
tion to the model and believe that the principle of the 
model is correct and the existing problems in this model 
are common as compared with other crystallization mod-
el systems in vitro. In our own experience, the cur-
rently used Coulter Counter model looks good for evalu-
ation of inhibitory activity of single and pure inhibitors 
such as GAGs and the results can be compared with 
Constant Composition model. But, for a complex sam-
ple such as human urine, the model may sometimes have 
deficiencies because urine composition cannot be con-
trolled. Moreover, because they have to be diluted (usu-
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ally to around 1 %), different inhibitors are diluted to 
varying extents, and the resulting overall activity may 
bear no relation to the inhibitory effect that the urine 
may have on CaOx crystallization in the undiluted state. 
These difficulties, perhaps, concern study on method-
ological standardization. In our opinion, the main 
problem of this model is how to record and evaluate 
the extra fine particles and extra large particles. The 
former has gone beyond the detection range of Coul-
ter Counter single tube technique and the latter may 
related to additional foreign catalytic surf ace. Both 
extra fine and large particles may associated with the 
possibility of second nucleation, de-agglomeration of 
poly-crystals and additional foreign catalytic surface. 
For instance, a potential secondary nucleation induced 
by adding G872 to human urine, as pointed out by Dr. 
Nancollas, could not be detected with the single tube 
technique of Coulter Counter. 
R.L. Ryall: I firmly believe that the model you used, 
and which you point out, we have used ourselves, has 
much to offer stone research. However, there are two 
factors that need to be taken into account: (a) Coulter 
Counter data need to be corrected to take account of the 
deficiencies I have listed. (b) Data must not be used to 
draw conclusions about an inhibitor's possible action in 
urine in vivo. In addition, even you find that the model 
"looks good for evaluation of inhibitory activity of a 
single and pure inhibitors such as GAGs," I can only 
stress, once again, that the data are only useful to draw 
conclusions about an inhibitor's action in an inorganic 
solution. For example, chondroitin is a powerful inhibi-
tor of aggregation in a seeded, inorganic metastable so-
lution, but it has no material effect in urine and this is 
perfectly in keeping with its absence from both CaOx 
stone and crystals. Could you explain in detail the real 
difference between aggregation and agglomeration? The 
term "agglomeration" has crept into stone research in re-
cent years with no author ever bothering to explain its 
meamng. 
Authors: We agree with your principle mentioned in 
(a) and (b), and are glad to hear that Drs. Hounslow and 
Bramley of the University of Cambridge are willing to 
help us in improving our current model. However, we 
think that any results from any in vitro crystallization 
model systems used currently may not completely repre-
sent the situations in whole urine and in vivo. Your ex-
ample about the absence of chondroitin in stone matrix 
and crystal matrix does not exclude the role of chondroi-
tin in stone formation. More recent evidence [ 40] has 
demonstrated the difference of chondroitin between 
stone-formers and non-stone-formers. Considering a 
change of available surface area of seeded crystals in-
duced by crystal flocculation or coagulation, which may 
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have an influence on crystal growth, it could be neces-
sary to define the terms of aggregation and agglomera-
tion. Nancollas [22] stated: "The terms flocculation and 
coagulation refer to the tendency for small suspended 
particles in a liquid to form aggregates or agglomerates. 
Aggregates may be regarded as groups of primary parti-
cles joined at their faces and having surface areas signif-
icantly less than the sum of the areas of their constituent 
particles. In agglomeration, the primary particles may 
be regarded as being joined at edges and comers so that 
the surface area of the resulting particles is not markedly 
different from the sum of the areas of the individual 
components." We suppose that agglomeration could be 
a main manner of crystal flocculation in the used Coulter 
Counter model. 
S.R. Khan: Why is there so little difference in inhibi-
tion and agglomeration between the normals and the 
stone formers, and yet the ZP is much lower for the 
stone formers? 
R.L. Ryall: For the data presented in Figure 2, all 
urines were centrifuged at 1500 x g for 10 minutes and 
were also frozen at -20°C. It is known that such treat-
ment may cause the loss of substantial amounts of THP 
[35] and induce precipitation of urinary proteins and 
CaOx crystal [37) . Did the authors check the effects of 
their urine treatment procedures on THP and total pro-
tein and GAG concentrations? What steps were taken to 
ensure after thawing that precipitated macromolecules 
and crystals were completely redissolved? Were the ef-
fect of freezing and thawing on ZP and inhibitory activ-
ity measurements checked? 
Authors: We do not know why no significant differ-
ence of urinary inhibitory activity was found in this 
study between stone patients and normals. Too small 
sample count (n = 10 for each) could be one of the rea-
sons because we found a significant difference of these 
parameters in our previous investigation [34]. A second 
reason could be related to treatment and store of the 
urine samples which we shall seriously consider check-
ing the influence of urinary pretreatment on the results 
of urinary inhibitory activity and ZP. It may be neces-
sary to mention that only 5 ml urine for each individual 
samples underwent such treatment, because we were 
pressed for time. The pooled urine and various urinary 
fractions were prepared without centrifuging and 
freezing stone procedures. 
G.H. Nancollas: The zeta potential is an extremely 
sensitive parameter for measuring changes in surface 
charge. In order to make proper comparisons, the iso-
electric point is more useful. The authors should make 
ZP measurements as a function of pH on both the COM 
pure surfaces and those which have been coated with the 
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macromolecules of interest. In the ZP measurements, 
the COM crystal were re-suspended in diluted artificial 
urine. This contains considerable concentrations of 
phosphate ion and it is quite possible that other phases 
(e.g., calcium phosphates) will precipitate on the crystal 
surface. Did the authors do energy-dispersive X-ray 
(EDX) measurements in order to verify that this did not 
occur? 
R.L. Ryall: Why were the zeta potential measurements 
made in artificial urine and not measured directly in the 
urine samples, which would more accurately reflect 
physiological conditions? 
Authors: Although it is not difficult to measure directly 
the ZP of COM crystals in whole urine, the results from 
such whole urine could be difficult to evaluate due to 
undefined pH, ionic strength and other reasons. The 
new approach of the ZP measurement presented in this 
paper may overcome the above difficulties. After incu-
bation of COM crystals in whole urine, the COM crys-
tals coated by urinary macromolecules have all original 
feature of these compounds and the results from re-sus-
pending COM in artificial urine can fully reflect the 
characteristics of urinary macromolecules. The precipi-
tation of calcium phosphate on COM could occur in re-
suspension process as pointed out by Dr. Nancollas, 
therefore, the suggested EDX measurements should be 
done later. 
H.G. Tiselius: From a therapeutic/prophylactic point of 
view, the effects of G872 appear promising and the ef-
fects on the ZP are obviously reflected in corresponding 
changes in the crystal size distribution. In these experi-
ments, G872 was added to give a final concentration of 
5 mg/l. Is it likely that this concentration can be at-
tained in urine following an oral load of this prepara-
tion? 
Authors: Little is known about metabolism of endoge-
nous GAGs as well as exogenous sulfated polysaccha-
rides, such as, G872. The final concentration of 5 mg/l 
was chosen according to the pharmacokinetic study of 
SP54 [36]. The results from in vitro models suggest po-
tential use of G872 for stone prevention, however, the 
actual situations concerning the role of G872 in stone-
forming rats and human urolithiasis are much complex. 
Up to now, we could not measure the precise amount of 
urinary G872 following an oral load. Moreover, we 
could not find a significant increase of total GAGs ex-
cretion as well as of urinary inhibitory activity in stone-
forming rats induced with ethylene glycol and vitamin 
D3 following oral G872 administration. However, a 
preliminary clinical study demonstrated a significant in-
crease of urinary GAGs excretion following oral G872 
administration (200 mg/day). This may suggest a differ-
ent metabolic response to G872 between humans and rats. 
L.C. Cao et al. 
S.R. Khan: Why are the normal urines pooled and not 
the stone former urines? 
R.L. Ryall: I am afraid that I still cannot agree with 
your statement about the protective effect of THP on uri-
nary macromolecular inhibitors, because you did not 
perform any experiments to examine molecular defects 
of urinary inhibitors. 
Authors: Indeed, in the present study no special at-
tempt was made to identify the difference of urinary in-
hibitors between SF and NSF. However, an irreversible 
process was found in THPFU {see eq. (5) and corre-
sponding text for details}, but was not in PNU which 
prompted us to make the speculation about protective 
effect of THP. 
R.L. Ryall: The procedure you use for removing THP 
is very good. However, I must ask you whether you are 
certain whether the diatomaceous earth procedure you 
use removes only THP. Are you certain that all the 
other macromolecules are not removed? 
Authors: The result from ELISA [2] suggest that all 
urinary THP can be removed from original urine using 
the diatomaceous earth procedure. But, we are not sure 
whether other urinary macromolecules are also removed. 
This point needs to be investigated further. 
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